American Gene Technologies: Addressing the World’s Endemic Diseases
AGT is developing and commercializing genetic medicines targeting major diseases
Alumni Ventures portfolio company American Gene Technologies (AGT) is developing and commercializing genetic medicines targeting major diseases, including HIV/AIDS, phenylketonuria, and hepatocellular carcinoma (liver cancer, or HCC). AGT’s drugs will treat symptomatic disease with the intent to provide durable cures that extend the length and improve the quality of patients’ lives.
About American Gene Technologies
AGT is a biopharmaceutical company developing genetic medicines that meet unmet medical needs in inherited or acquired diseases through the application of viral vector technology.
The company is focused on achieving permanent cures that provide long-term value for patients, society, investors, and donors by developing and testing cutting-edge gene therapies to cure some of humanity’s worst diseases.
Enterprise clients turn to AGT for:
- Home
Extensive catalog of patented treatments for diseases
- Home
Revolutionary treatment for HIV
- Home
Proven expertise in the fields of medicine and gene therapy
- Home
Rapid development of drugs to treat inherited diseases
- Home
An industry leader in genetic design and development
Meet AGT Founder & CEO Jeff Galvin
Jeff Galvin earned his BA in Economics from Harvard in 1981. He has more than 30 years of business and entrepreneurial experience, including founder or executive positions at a variety of Silicon Valley startups.
Several of his companies were taken public and/or sold to public companies, including one in the medical-technology arena that was sold to Varian, the leading maker of linear accelerators used in cancer therapy. Following his startup experience, Jeff retired to become an angel investor in real estate and high tech.
He came out of retirement in 2006 to found and fund AGT after meeting the late Roscoe Brady, who introduced Galvin to tools called “viral vectors” that enable molecular biologists to deliver genetic material into cells. Brady spent more than 50 years at the National Institute of Health conducting pioneering research on hereditary diseases.
Watch an interview with Jeff and AV Managing Partner Greg Baker.
See video policy below.
A Pioneer of New Disease Treatments
AGT’s HIV cure has shown promise in creating a powerful drug that may bring relief to one of society’s most elusive epidemics and prove the efficiency and effectiveness of AGT’s platform technologies to cure dozens of diseases ranging from viruses to cancers.
In 2019, AGT signed a Research Collaboration Agreement with the National Institute of Allergy and Infectious Diseases (part of the NIH). In 2021, AGT announced that clinical trials indicate its HIV cure should be able to create an effective immune response against HIV in the absence of antiretroviral treatment.
AGT has raised over $78 million to date based on the strength of its intellectual property portfolio, the broad market potential of its primary product, and its team’s understanding of disease treatments. Here are aspects of the deal that our team found compelling:
What We Liked About AGT
- Home
Unique IP and Tech
With an estimated value in the billions, AGT’s technology can be applied to a broader set of diseases more efficiently and effectively. The company has 23 patent families in various stages with six granted patents. AGT is working with researchers and experts from top institutions who have the ne - Home
Flagship Products
The company is developing single treatment cures that can eliminate a lifetime of chronic care symptom management and treatments. Their solutions offer targeted and locally administered therapies that do not cause systemic toxicities, such as chemotherapy. AGT is building a drug-delivery platform to develop a variety of therapeutics and cures for various diseases. - Home
An Established Organization
AGT has developed significant assets accrued over a decade of development. Ten years of lentiviral vector experience and platform development position the company head and shoulders above its nearest competitors.
How We’re Involved
- $16 million Series D1 in 2018 alongside the National Institutes of Health
- $50 million Series F in 2022 led by Ride Wave Ventures
AV Funds Invested in AGT
- Bascom Ventures (for the Wisconsin community)
- Towerview Ventures (for the Duke community)
- Healthtech Fund (healthtech and life sciences innovations)
- Impact Fund (impactful social and environmental ventures)
- Total Access Fund (our broadest fund)
Want to learn more?
View all our available funds and secure data rooms, or schedule an intro call.
New to AV?
Sign up and access exclusive venture content.
Contact [email protected] for additional information. To see additional risk factors and investment considerations, visit av-funds.com/disclosures.